Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience.

ABSTRACT: Immunotherapy has revolutionized outcomes for melanoma patients, by significantly prolonging survival and probably even curing a fraction of metastatic patients. In daily practice, treatment for responding patients is often discontinued due to treatment-limiting toxicity, or electively, following a major tumor response. To date, the criteria for a safe stop and the optimal duration of treatment remain unclear. This is a real-world single-site cohort of 106 advanced melanoma patients who were treated with immunotherapy and who discontinued treatments in the absence of disease progression. Here, we describe their long-term outcomes, and analyze the differential characteristics between patients who ultimately experienced progression and those who remained in unmaintained durable response. Pat

SUBMITTER: Asher N 

PROVIDER: S-EPMC8234591 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature